- |||||||||| latikafusp (AMG 256) / Amgen
Trial completion, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 25, 2023
P1, N=34, Completed,
The AMG 256 program represents a unique case where nonclinical studies informed on the risk of immunogenicity in humans, due to the IL-21-driven nature of the response. Active, not recruiting --> Completed
- |||||||||| latikafusp (AMG 256) / Amgen
Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 21, 2023
P1, N=34, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Nov 2024 --> Sep 2023
- |||||||||| latikafusp (AMG 256) / Amgen
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2022
P1, N=34, Active, not recruiting,
Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Nov 2024 --> Sep 2023 N=100 --> 34 | Trial completion date: May 2026 --> Nov 2024 | Trial primary completion date: May 2026 --> Nov 2024
- |||||||||| latikafusp (AMG 256) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 29, 2022
P1, N=100, Active, not recruiting,
N=100 --> 34 | Trial completion date: May 2026 --> Nov 2024 | Trial primary completion date: May 2026 --> Nov 2024 Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> May 2026
- |||||||||| latikafusp (AMG 256) / Amgen
Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 9, 2022
P1, N=100, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> May 2026 Trial primary completion date: Aug 2023 --> Oct 2025
- |||||||||| latikafusp (AMG 256) / Amgen
Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 15, 2021
P1, N=100, Recruiting,
Trial primary completion date: Aug 2023 --> Oct 2025 Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Mar 2023 --> Aug 2023
- |||||||||| AMG 256 / Amgen
[VIRTUAL] Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_3893;
P1
The primary endpoints are incidence of dose-limiting toxicities and adverse events, MTD, and recommended phase 2 dose. Secondary objectives will evaluate PK parameters, preliminary antitumor activity (objective response, duration of response, progression-free survival, disease control rate, duration of stable disease, overall survival), and immunogenicity of AMG 256 via incidence of anti-AMG 256 antibodies.
- |||||||||| latikafusp (AMG 256) / Amgen
Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2020
P1, N=100, Recruiting,
Secondary objectives will evaluate PK parameters, preliminary antitumor activity (objective response, duration of response, progression-free survival, disease control rate, duration of stable disease, overall survival), and immunogenicity of AMG 256 via incidence of anti-AMG 256 antibodies. Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: Nov 2023 --> Mar 2023
- |||||||||| AMG 256 / Amgen
[VIRTUAL] Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors () - Oct 14, 2020 - Abstract #SITC2020SITC_1448;
P1
Secondary objectives will evaluate PK parameters, preliminary antitumor activity (objective response, duration of response, progression-free survival, disease control rate, duration of stable disease, overall survival), and immunogenicity of AMG 256 via incidence of anti-AMG 256 antibodies. Results N/A Conclusions N/A
- |||||||||| AMG 256 / Amgen
[VIRTUAL] Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors () - Oct 14, 2020 - Abstract #SITC2020SITC_713;
P1
Secondary objectives will evaluate PK parameters, preliminary antitumor activity (objective response, duration of response, progression-free survival, disease control rate, duration of stable disease, overall survival), and immunogenicity of AMG 256 via incidence of anti-AMG 256 antibodies. Results N/A Conclusions N/A
- |||||||||| latikafusp (AMG 256) / Amgen
Trial completion date, Trial primary completion date, Metastases: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 14, 2020
P1, N=100, Not yet recruiting,
Not yet recruiting --> Recruiting Trial completion date: Jul 2022 --> Aug 2025 | Trial primary completion date: Feb 2022 --> Nov 2023
|
